Can-Fite Reports 2022 Financial Results & Provides Clinical Update

March 30, 2023 10:33 PM AEDT | By Reuters
Follow us on Google News:

March 30 (Reuters) - Can Fite Biopharma Ltd:

* CAN-FITE REPORTS 2022 FINANCIAL RESULTS & PROVIDES CLINICAL UPDATE

* CAN FITE BIOPHARMA LTD - AS OF DEC 31, 2022, HAD CASH, CASH EQUIVALENTS, AND SHORT-TERM DEPOSITS OF $7.97 MILLION

* CAN FITE BIOPHARMA LTD - FY NET LOSS WAS $10.17 MILLION VERSUS NET LOSS OF $12.61 MILLION

* CAN FITE BIOPHARMA: NAMODENOSON IS SHOWING POTENTIAL FOR EFFICACY ACROSS SEVERAL INDICATIONS FROM LIVER DISEASE TO PANCREATIC CANCER Source text for Eikon: Further company coverage:


Disclaimer

The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.



Top ASX Listed Companies

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK